Study Group: Rituxan Prescribers: Rheumatologists(?)
Council Members in this Study Group: 35
Request a survey with this Study Group
Leading Experts in this Study Group
Partner
San Diego Arthritis Medical Clinic
Ara Dikranian, MD, is a Rheumatologist at San Diego Arthritis Medical Clinic, a single-specialty private practice in San Diego, California. Dr. Dikranian is board certified in Internal Medicine and Rheumatology. He completed his rheumatology training at the University of California San Diego. He has...
Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested...
Avram Goldberg, MD,FACRAssistant Professor
Albert Einstein College of Medicine
Avram Goldberg, MD, FACR, is an Attending Physician at North Shore University Hospital and an Assistant Professor at the Albert Einstein College of Medicine, New York. He is part of the Division of Rheumatology where he is responsible for treatment of autoimmune and musculoskeletal diseases including...
Rheumatologist
Arthritis and Osteoporosis Treatment Center
Kenneth Nies, MD, FACP, is a Clinical Professor of Medicine at the University of California Los Angeles and is also in private practice at the Arthritis and Osteoporosis Treatment Center in Torrance, California. In addition to his clinical work, his background includes 10 years of academic medicine...
Carl M. Pearson Chair of Rheumatology
UNIVERSITY OF CALIFORNIA LOS ANGELES
Daniel Furst, MD, is the Carl M. Pearson Chair of Rheumatology and Director of Interventional Therapeutics at University of California, Los Angeles Medical Center for Health Sciences. Dr. Furst has expertise in clinical pharmacology of anti-rheumatic drugs, scleroderma, and rheumatoid arthritis.
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...
Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is...
Very important new treatment emerging in field of rheumatoid arthritis along with other drugs in pipeline. IL-6 receptor blocker. New Mechanism of action. Has positive priliminary endpoint results at 24 week study for RA compared to DMARD therapy alone.
Very nice article. Although sample size seemed very less, avaialble results look very promising. Particularly in contrast of Leevy study. Only concern is of side-effects. Would make things clear on further study with the same drug
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Director
- Physician - Division Head
- Professor
- Medical Director
- Partner
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

